Evidence map›Paper›PMID 40165350›Full record

ArticleJournal of psychopharmacology (Oxford, England)2025

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.

Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke, Peter Gasser, William A Richards, Thomas G Riemer, Ricarda Evens

Registry-linked trialAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07737990 (Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07737990 naenrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

TypeinterventionalSponsorJoshua RosenblatRan2026 to 2030Enrolled65ConditionsTreatment-resistant Depression (TRD)ArmsGroup integration therapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Classifying Psychedelic-Related Complications.Current topics in behavioral neurosciences · 2026
    Review
  2. Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.Current topics in behavioral neurosciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tomislav MajićDepartment of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0003-2950-6673
Timo Torsten SchmidtDepartment of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0003-1612-1301
Anna GrötickeDepartment of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Peter GasserMedical Office for Psychiatry and Psychotherapy, Solothurn, Switzerland.
William A RichardsThe Bill Richards Center for Healing, Sunstone Therapies, Rockville, MD, USA.ORCID 0000-0003-0730-9249
Thomas G RiemerDepartment of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Ricarda EvensDepartment of Psychiatry and Psychotherapy, Berlin Institute of Health, Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-2834-2171

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClassic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of "psychedelic afterglow," a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute "afterglow" effects is needed.

aimsTo create and validate a questionnaire to quantify the subacute "afterglow" effects of psychedelics.

methodsAn international online survey was conducted in English and German. Participants who had consumed a psychedelic (

resultsA 5-factor structure best fit the data and showed high internal consistency. The factors included (1) vitality, (2) transpersonal aspects, (3) inspiration/creativity, (4) interpersonal relationships, and (5) relationship to nature. The final 24-item version of the Afterglow Inventory (AGI) effectively differentiated between the psychedelic group and the control group. The overall AGI score positively correlated with the intensity (

conclusionsThe AGI is a novel scale for quantifying positive subacute ("afterglow") effects of psychedelics. The use of the AGI could lead to a better understanding of the interplay between acute, subacute, and long-term effects of psychedelics. Insights could also be gained into how different substances, dosages, and extra-pharmacological factors, such as psychotherapy, might influence outcomes.

Indexed as

HallucinogensAdolescentAdultFemaleHumansLysergic Acid DiethylamideMaleMiddle AgedPsilocybinPsychometricsReproducibility of ResultsSurveys and QuestionnairesYoung AdultHallucinogensLysergic Acid DiethylamidePsilocybinafterglowassessmentPsychedelicquestionnairesubacute

Identifiers

PMID40165350
PMCPMC12099019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.